Dublin, Oct. 09, 2017 -- The "Global Active Pharmaceutical Ingredients (API) Market Analysis & Trends - Industry Forecast to 2025" report has been added to Research and Markets' offering.
The Global Active Pharmaceutical Ingredients (API) Market is poised to grow at a CAGR of around 6.6% over the next decade to reach approximately $238.8 billion by 2025.
Some of the prominent trends that the market is witnessing include, Growing Geriatric Population, Rapid growth in biopharmaceuticals sector and Technological Advancements in API Manufacturing.
Based on Therapeutic Area, the market is segregated into oncology, nsaids, neurological disorders, musculoskeletal disorders, cardiovascular disorders, metabolic disorders and other therapeutics uses.
By Drug Type, the market is categorized into OTC prescription drugs, generic prescription drugs and branded prescription drugs. On the basis of Manufacturing Process, the market is segmented into contract manufacturing and captive manufacturing.
Depending on API Type the market is divided into biological API, synthetic chemical API and high potency active pharmaceutical ingredients (HPAPI). The Biological API segment is further categorized into Biotech and Biosimilar. The Synthetic Chemical API segment is further divided into branded/ innovative and generic/non- branded.
This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2014, 2015 revenue estimations are presented for 2016 and forecasts from 2017 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
Report Highlights:
- The report provides a detailed analysis on current and future market trends to identify the investment opportunities
- Market forecasts till 2025, using estimated market values as the base numbers
- Key market trends across the business segments, Regions and Countries
- Key developments and strategies observed in the market
- Market Dynamics such as Drivers, Restraints, Opportunities and other trends
- In-depth company profiles of key players and upcoming prominent players
- Growth prospects among the emerging nations through 2025
- Market opportunities and recommendations for new investments
Key Topics Covered:
1 Market Outline
2 Executive Summary
3 Market Overview
3.1 Current Trends
3.1.1 Growing Geriatric Population
3.1.2 Rapid growth in biopharmaceuticals sector
3.1.3 Technological Advancements in Api Manufacturing
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness
4 Active Pharmaceutical Ingredients (API) Market, By Therapeutic Area
4.1 Oncology
4.2 NSAIDs
4.3 Neurological Disorders
4.4 Musculoskeletal Disorders
4.5 Cardiovascular Disorders
4.6 Metabolic Disorders
4.7 Other Therapeutics Uses
5 Active Pharmaceutical Ingredients (API) Market, By Drug Type
5.1 OTC Prescription Drugs
5.2 Generic Prescription Drugs
5.3 Branded Prescription Drugs
6 Active Pharmaceutical Ingredients (API) Market, By Manufacturing Process
6.1 Contract Manufacturing
6.2 Captive Manufacturing
7 Active Pharmaceutical Ingredients (API) Market, By API Type
7.1 Biological API
7.1.1.1 Biotech
7.1.1.2 Biosimilar
7.2 Synthetic Chemical API
7.2.1.1 Branded/ Innovative
7.2.1.2 Generic/Non- Branded
7.3 High potency active pharmaceutical ingredients(HPAPI)
8 Active Pharmaceutical Ingredients (API) Market, By Geography
9 Key Player Activities
9.1 Acquisitions & Mergers
9.2 Agreements, Partnerships, Collaborations and Joint Ventures
9.3 Product Launch & Expansions
9.4 Other Activities
10 Leading Companies
- Teva Pharmaceutical Industries Limited
- Sun Pharmaceutical Industries Ltd.
- Merial Inc. (Sanofi) (France)
- Merck Animal Health (U.S.)
- Elanco Animal Health (U.S.)
- Dr. Reddy's Laboratories Ltd.
- Ceva Animal Health, Inc.
- Boehringer Ingelheim (Germany)
- Bioniche Animal Health (Canada)
- Aurobindo Pharma Ltd.
- Bayer Healthcare (Germany)
- Heska Co. (U.S.)
- Novartis International AG
- Pfizer, Inc
- Zoetis (U.S.)
- Virbac
- Ranbaxy Laboratories
For more information about this report visit https://www.researchandmarkets.com/research/5jl2gn/global_active
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals


Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 



